Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Completed1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07313982RecruitingPrimary

LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION

NCT06958705Phase 2RecruitingPrimary

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

NCT07173790Enrolling By InvitationPrimary

Watch and Wait or Worry and Wait in Indolent Lymphoma

NCT01994382Phase 1Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Showing all 4 trials

Research Network

Activity Timeline